View Financial HealthKronox Lab Sciences 배당 및 자사주 매입배당 기준 점검 3/6Kronox Lab Sciences 수익으로 충분히 충당되는 현재 수익률 0.37% 보유한 배당금 지급 회사입니다.핵심 정보0.4%배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향7%최근 배당 및 자사주 매입 업데이트Upcoming Dividend • Aug 01Upcoming dividend of ₹0.50 per shareEligible shareholders must have bought the stock before 08 August 2025. Payment date: 17 September 2025. Payout ratio is a comfortable 7.3% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.7%).공시 • Jul 26Kronox Lab Sciences Limited announces Annual dividend, payable on September 17, 2025Kronox Lab Sciences Limited announced Annual dividend of INR 0.5000 per share payable on September 17, 2025, ex-date on August 08, 2025 and record date on August 08, 2025.모든 업데이트 보기Recent updates공시 • May 15Kronox Lab Sciences Limited to Report Q4, 2026 Results on May 20, 2026Kronox Lab Sciences Limited announced that they will report Q4, 2026 results at 12:08 PM, Indian Standard Time on May 20, 2026Buy Or Sell Opportunity • Apr 06Now 27% overvaluedOver the last 90 days, the stock has fallen 5.1% to ₹132. The fair value is estimated to be ₹104, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.2% over the last 3 years. Earnings per share has grown by 18%.Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹118, the stock trades at a trailing P/E ratio of 17x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 17% over the past year.Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹1.79 (vs ₹1.77 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.79 (up from ₹1.77 in 3Q 2025). Revenue: ₹264.1m (up 10.0% from 3Q 2025). Net income: ₹65.9m (flat on 3Q 2025). Profit margin: 25% (down from 27% in 3Q 2025). The decrease in margin was driven by higher expenses.공시 • Feb 09Kronox Lab Sciences Limited to Report Q3, 2026 Results on Feb 14, 2026Kronox Lab Sciences Limited announced that they will report Q3, 2026 results at 12:08 PM, Indian Standard Time on Feb 14, 2026Reported Earnings • Nov 12Second quarter 2026 earnings released: EPS: ₹1.82 (vs ₹1.76 in 2Q 2025)Second quarter 2026 results: EPS: ₹1.82 (up from ₹1.76 in 2Q 2025). Revenue: ₹265.8m (up 6.9% from 2Q 2025). Net income: ₹66.8m (up 3.1% from 2Q 2025). Profit margin: 25% (in line with 2Q 2025).공시 • Nov 04Kronox Lab Sciences Limited to Report Q2, 2026 Results on Nov 11, 2025Kronox Lab Sciences Limited announced that they will report Q2, 2026 results on Nov 11, 2025Board Change • Sep 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Non Executive-Independent Women Director Krutika Negandhi was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Aug 06Kronox Lab Sciences Limited to Report Q1, 2026 Results on Aug 11, 2025Kronox Lab Sciences Limited announced that they will report Q1, 2026 results on Aug 11, 2025Upcoming Dividend • Aug 01Upcoming dividend of ₹0.50 per shareEligible shareholders must have bought the stock before 08 August 2025. Payment date: 17 September 2025. Payout ratio is a comfortable 7.3% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.7%).Reported Earnings • Jul 29Full year 2025 earnings released: EPS: ₹6.86 (vs ₹5.75 in FY 2024)Full year 2025 results: EPS: ₹6.86 (up from ₹5.75 in FY 2024). Revenue: ₹1.00b (up 12% from FY 2024). Net income: ₹254.7m (up 19% from FY 2024). Profit margin: 25% (up from 24% in FY 2024). The increase in margin was driven by higher revenue.공시 • Jul 28Kronox Lab Sciences Limited, Annual General Meeting, Aug 18, 2025Kronox Lab Sciences Limited, Annual General Meeting, Aug 18, 2025, at 11:00 Indian Standard Time.공시 • Jul 26Kronox Lab Sciences Limited announces Annual dividend, payable on September 17, 2025Kronox Lab Sciences Limited announced Annual dividend of INR 0.5000 per share payable on September 17, 2025, ex-date on August 08, 2025 and record date on August 08, 2025.Buy Or Sell Opportunity • Jul 07Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 45% to ₹202. The fair value is estimated to be ₹168, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.3% over the last 3 years. Earnings per share has grown by 22%.Valuation Update With 7 Day Price Move • Jun 26Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹188, the stock trades at a trailing P/E ratio of 27.3x. Average trailing P/E is 29x in the Chemicals industry in India. Total returns to shareholders of 25% over the past year.Valuation Update With 7 Day Price Move • May 30Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹172, the stock trades at a trailing P/E ratio of 25.1x. Average trailing P/E is 27x in the Chemicals industry in India.Reported Earnings • May 23Full year 2025 earnings released: EPS: ₹6.91 (vs ₹5.75 in FY 2024)Full year 2025 results: EPS: ₹6.91 (up from ₹5.75 in FY 2024). Revenue: ₹1.03b (up 14% from FY 2024). Net income: ₹254.7m (up 19% from FY 2024). Profit margin: 25% (up from 24% in FY 2024). The increase in margin was driven by higher revenue.공시 • May 19Kronox Lab Sciences Limited to Report Q4, 2025 Results on May 22, 2025Kronox Lab Sciences Limited announced that they will report Q4, 2025 results on May 22, 2025Reported Earnings • Feb 02Third quarter 2025 earnings released: EPS: ₹1.77 (vs ₹1.29 in 3Q 2024)Third quarter 2025 results: EPS: ₹1.77 (up from ₹1.29 in 3Q 2024). Revenue: ₹248.3m (up 20% from 3Q 2024). Net income: ₹65.3m (up 38% from 3Q 2024). Profit margin: 26% (up from 23% in 3Q 2024). The increase in margin was driven by higher revenue.공시 • Jan 23Kronox Lab Sciences Limited to Report Q3, 2025 Results on Jan 31, 2025Kronox Lab Sciences Limited announced that they will report Q3, 2025 results on Jan 31, 2025Valuation Update With 7 Day Price Move • Nov 27Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹191, the stock trades at a trailing P/E ratio of 30.5x. Average trailing P/E is 32x in the Chemicals industry in India.New Risk • Nov 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Market cap is less than US$100m (₹6.87b market cap, or US$81.4m).공시 • Oct 31Kronox Lab Sciences Limited to Report Q2, 2025 Results on Nov 12, 2024Kronox Lab Sciences Limited announced that they will report Q2, 2025 results on Nov 12, 2024Valuation Update With 7 Day Price Move • Oct 14Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹175, the stock trades at a trailing P/E ratio of 30.8x. Average trailing P/E is 35x in the Chemicals industry in India.Valuation Update With 7 Day Price Move • Aug 29Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹182, the stock trades at a trailing P/E ratio of 31.9x. Average trailing P/E is 36x in the Chemicals industry in India.공시 • Aug 09Kronox Lab Sciences Limited, Annual General Meeting, Aug 30, 2024Kronox Lab Sciences Limited, Annual General Meeting, Aug 30, 2024, at 11:00 Indian Standard Time. Location: Block no. 353, Village: Ekalbara, Taluka: Padra, District: Vadodara 391440 IndiaReported Earnings • Aug 07First quarter 2025 earnings released: EPS: ₹1.67 (vs ₹0.64 in 1Q 2024)First quarter 2025 results: EPS: ₹1.67 (up from ₹0.64 in 1Q 2024). Revenue: ₹256.2m (up 19% from 1Q 2024). Net income: ₹61.5m (up 152% from 1Q 2024). Profit margin: 24% (up from 11% in 1Q 2024). The increase in margin was driven by higher revenue.공시 • Jul 29Kronox Lab Sciences Limited to Report Q1, 2025 Results on Aug 06, 2024Kronox Lab Sciences Limited announced that they will report Q1, 2025 results on Aug 06, 2024공시 • Jun 22Kronox Lab Sciences Limited to Report Q4, 2024 Results on Jun 28, 2024Kronox Lab Sciences Limited announced that they will report Q4, 2024 results on Jun 28, 2024Board Change • Jun 11Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Satish Kumar was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 배당금 지급이 안정적인 반면, 544187 은(는) 배당금을 지급한 지 10년도 채 되지 않았습니다.배당금 증가: 544187 2 년 동안만 배당금을 지급해 왔으며 그 이후로 지급액이 증가하지 않았습니다.배당 수익률 vs 시장Kronox Lab Sciences 배당 수익률 vs 시장544187의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (544187)0.4%시장 하위 25% (IN)0.3%시장 상위 25% (IN)1.5%업계 평균 (Chemicals)0.7%분석가 예측 (544187) (최대 3년)n/a주목할만한 배당금: 544187 의 배당금( 0.37% )은 Indian 시장에서 배당금 지급자의 하위 25%( 0.3% )보다 높습니다.고배당: 544187 의 배당금( 0.37% )은 Indian 시장에서 배당금 지급자의 상위 25%( 1.48% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: 낮은 배당금 지급 비율 (7.2%)로 인해 544187의 배당금 지급은 수익으로 충분히 충당됩니다.주주 현금 배당현금 흐름 범위: 현금 지급 비율 ( 8.1% )이 낮기 때문에 544187 의 배당금 지급은 현금 흐름으로 완전히 충당됩니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YIN 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 09:43종가2026/05/21 00:00수익2025/12/31연간 수익2025/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Kronox Lab Sciences Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Upcoming Dividend • Aug 01Upcoming dividend of ₹0.50 per shareEligible shareholders must have bought the stock before 08 August 2025. Payment date: 17 September 2025. Payout ratio is a comfortable 7.3% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.7%).
공시 • Jul 26Kronox Lab Sciences Limited announces Annual dividend, payable on September 17, 2025Kronox Lab Sciences Limited announced Annual dividend of INR 0.5000 per share payable on September 17, 2025, ex-date on August 08, 2025 and record date on August 08, 2025.
공시 • May 15Kronox Lab Sciences Limited to Report Q4, 2026 Results on May 20, 2026Kronox Lab Sciences Limited announced that they will report Q4, 2026 results at 12:08 PM, Indian Standard Time on May 20, 2026
Buy Or Sell Opportunity • Apr 06Now 27% overvaluedOver the last 90 days, the stock has fallen 5.1% to ₹132. The fair value is estimated to be ₹104, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.2% over the last 3 years. Earnings per share has grown by 18%.
Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹118, the stock trades at a trailing P/E ratio of 17x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 17% over the past year.
Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹1.79 (vs ₹1.77 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.79 (up from ₹1.77 in 3Q 2025). Revenue: ₹264.1m (up 10.0% from 3Q 2025). Net income: ₹65.9m (flat on 3Q 2025). Profit margin: 25% (down from 27% in 3Q 2025). The decrease in margin was driven by higher expenses.
공시 • Feb 09Kronox Lab Sciences Limited to Report Q3, 2026 Results on Feb 14, 2026Kronox Lab Sciences Limited announced that they will report Q3, 2026 results at 12:08 PM, Indian Standard Time on Feb 14, 2026
Reported Earnings • Nov 12Second quarter 2026 earnings released: EPS: ₹1.82 (vs ₹1.76 in 2Q 2025)Second quarter 2026 results: EPS: ₹1.82 (up from ₹1.76 in 2Q 2025). Revenue: ₹265.8m (up 6.9% from 2Q 2025). Net income: ₹66.8m (up 3.1% from 2Q 2025). Profit margin: 25% (in line with 2Q 2025).
공시 • Nov 04Kronox Lab Sciences Limited to Report Q2, 2026 Results on Nov 11, 2025Kronox Lab Sciences Limited announced that they will report Q2, 2026 results on Nov 11, 2025
Board Change • Sep 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Non Executive-Independent Women Director Krutika Negandhi was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Aug 06Kronox Lab Sciences Limited to Report Q1, 2026 Results on Aug 11, 2025Kronox Lab Sciences Limited announced that they will report Q1, 2026 results on Aug 11, 2025
Upcoming Dividend • Aug 01Upcoming dividend of ₹0.50 per shareEligible shareholders must have bought the stock before 08 August 2025. Payment date: 17 September 2025. Payout ratio is a comfortable 7.3% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.7%).
Reported Earnings • Jul 29Full year 2025 earnings released: EPS: ₹6.86 (vs ₹5.75 in FY 2024)Full year 2025 results: EPS: ₹6.86 (up from ₹5.75 in FY 2024). Revenue: ₹1.00b (up 12% from FY 2024). Net income: ₹254.7m (up 19% from FY 2024). Profit margin: 25% (up from 24% in FY 2024). The increase in margin was driven by higher revenue.
공시 • Jul 28Kronox Lab Sciences Limited, Annual General Meeting, Aug 18, 2025Kronox Lab Sciences Limited, Annual General Meeting, Aug 18, 2025, at 11:00 Indian Standard Time.
공시 • Jul 26Kronox Lab Sciences Limited announces Annual dividend, payable on September 17, 2025Kronox Lab Sciences Limited announced Annual dividend of INR 0.5000 per share payable on September 17, 2025, ex-date on August 08, 2025 and record date on August 08, 2025.
Buy Or Sell Opportunity • Jul 07Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 45% to ₹202. The fair value is estimated to be ₹168, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.3% over the last 3 years. Earnings per share has grown by 22%.
Valuation Update With 7 Day Price Move • Jun 26Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹188, the stock trades at a trailing P/E ratio of 27.3x. Average trailing P/E is 29x in the Chemicals industry in India. Total returns to shareholders of 25% over the past year.
Valuation Update With 7 Day Price Move • May 30Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹172, the stock trades at a trailing P/E ratio of 25.1x. Average trailing P/E is 27x in the Chemicals industry in India.
Reported Earnings • May 23Full year 2025 earnings released: EPS: ₹6.91 (vs ₹5.75 in FY 2024)Full year 2025 results: EPS: ₹6.91 (up from ₹5.75 in FY 2024). Revenue: ₹1.03b (up 14% from FY 2024). Net income: ₹254.7m (up 19% from FY 2024). Profit margin: 25% (up from 24% in FY 2024). The increase in margin was driven by higher revenue.
공시 • May 19Kronox Lab Sciences Limited to Report Q4, 2025 Results on May 22, 2025Kronox Lab Sciences Limited announced that they will report Q4, 2025 results on May 22, 2025
Reported Earnings • Feb 02Third quarter 2025 earnings released: EPS: ₹1.77 (vs ₹1.29 in 3Q 2024)Third quarter 2025 results: EPS: ₹1.77 (up from ₹1.29 in 3Q 2024). Revenue: ₹248.3m (up 20% from 3Q 2024). Net income: ₹65.3m (up 38% from 3Q 2024). Profit margin: 26% (up from 23% in 3Q 2024). The increase in margin was driven by higher revenue.
공시 • Jan 23Kronox Lab Sciences Limited to Report Q3, 2025 Results on Jan 31, 2025Kronox Lab Sciences Limited announced that they will report Q3, 2025 results on Jan 31, 2025
Valuation Update With 7 Day Price Move • Nov 27Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹191, the stock trades at a trailing P/E ratio of 30.5x. Average trailing P/E is 32x in the Chemicals industry in India.
New Risk • Nov 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Market cap is less than US$100m (₹6.87b market cap, or US$81.4m).
공시 • Oct 31Kronox Lab Sciences Limited to Report Q2, 2025 Results on Nov 12, 2024Kronox Lab Sciences Limited announced that they will report Q2, 2025 results on Nov 12, 2024
Valuation Update With 7 Day Price Move • Oct 14Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹175, the stock trades at a trailing P/E ratio of 30.8x. Average trailing P/E is 35x in the Chemicals industry in India.
Valuation Update With 7 Day Price Move • Aug 29Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹182, the stock trades at a trailing P/E ratio of 31.9x. Average trailing P/E is 36x in the Chemicals industry in India.
공시 • Aug 09Kronox Lab Sciences Limited, Annual General Meeting, Aug 30, 2024Kronox Lab Sciences Limited, Annual General Meeting, Aug 30, 2024, at 11:00 Indian Standard Time. Location: Block no. 353, Village: Ekalbara, Taluka: Padra, District: Vadodara 391440 India
Reported Earnings • Aug 07First quarter 2025 earnings released: EPS: ₹1.67 (vs ₹0.64 in 1Q 2024)First quarter 2025 results: EPS: ₹1.67 (up from ₹0.64 in 1Q 2024). Revenue: ₹256.2m (up 19% from 1Q 2024). Net income: ₹61.5m (up 152% from 1Q 2024). Profit margin: 24% (up from 11% in 1Q 2024). The increase in margin was driven by higher revenue.
공시 • Jul 29Kronox Lab Sciences Limited to Report Q1, 2025 Results on Aug 06, 2024Kronox Lab Sciences Limited announced that they will report Q1, 2025 results on Aug 06, 2024
공시 • Jun 22Kronox Lab Sciences Limited to Report Q4, 2024 Results on Jun 28, 2024Kronox Lab Sciences Limited announced that they will report Q4, 2024 results on Jun 28, 2024
Board Change • Jun 11Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Satish Kumar was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.